TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04244838

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Gait Analysis
Description: The patients will undergo Gait analysis (integrated movement analysis system) performed at the Complex Laboratory for Movement Analysis and functional-clinical evaluation of the prosthesis of the Rizzoli Orthopedic Institute. The instrumentation used in the Movement Analysis Laboratory consists of a stereophotogrammetric system equipped with eight infrared cameras (Vicon® 460-Oxford system) and 2 dynamometric platforms (Kistler® Instrument, AG Switzerland). The IOR GAIT protocol will be used as a marker set (Leardini et al. 2007). For the evaluation of muscle activation, surface electromyography with 16-channel system will be used (ZeroWire Cometa, Milan). Spatio-temporal parameters, kinematics, kinetics and muscle activation will be evaluated.
Study: NCT00822523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin, Type A
Description: 20 units, single dose, intramuscular in right EDB muscle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin, Type A
Description: 2 units, single dose, intramuscular to right EDB muscle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Single Dose, Intramuscular into right EDB muscle
Study: NCT02641574

Intervention type: OTHER
Intervention: compare complication

Intervention type: OTHER
Intervention: compare complication

Intervention type: OTHER
Intervention: compare complication

Intervention type: OTHER
Intervention: compare complication
Study: NCT01324596

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous
Description: Chemoimmunotheraphy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Chemoimmunotheraphy
Study: NCT04491266

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FBA
Description: N-(1-carbamoyl-2-phenyl-ethyl) butyramide (FBA) has been developed.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: maltodextrins
Study: NCT00760773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacidophil (experimental high dose)
Description: Each sachet will contain a minimum of 4 billion CFU/sachet. The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Subjects in this arm will receive the high dose which will consist of 4 billion CFU (1 active sachet) PO BID (total daily dose = 8 billion CFU) x 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacidophil (experimental standard dose)
Description: Each sachet will contain a minimum of 4 billion CFU/sachet. The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Subjects in this arm will receive the standard dose which will consist of 4 billion CFU (1 active sachet) PO QAM (total daily dose = 4 billion CFU) plus 1 placebo sachet PO QHS x 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated.
Study: NCT05367115

Intervention type: OTHER
Intervention: longitudinal observational study
Description: longitudinal observational study

Intervention type: OTHER
Intervention: longitudinal observational study
Description: longitudinal observational study

Intervention type: OTHER
Intervention: longitudinal observational study
Description: longitudinal observational study
Study: NCT01522469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenolanib Besylate (CP-868,596-26)
Description: Subjects will take crenolanib 200mg/m2/day divided in three doses daily (preferably every eight hours), taken orally at least 30 minutes pre or post meal until disease progression, death, or the patient discontinues treatment for adverse events, investigator's judgment, or other reasons. Patients who are able to proceed to allogeneic stem cell transplant will be able to resume crenolanib therapy post-transplant in an attempt to maintain remission.
Study: NCT04241601

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interleukin-2 [IL-2]
Description: Active Comparator: IL-2 plays a key role in Treg cell development, expansion, survival and suppressive function

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Dextrose 5% solution
Description: Placebo Comparator: Dextrose 5% solution
Study: NCT03083925

Intervention type: DEVICE
Intervention: TIPS
Description: Transjugular Intrahepatic Portosystemic Shunt
Study: NCT02439047

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biological samples collection
Description: -Peritoneal samples : will be collected during abdominal surgery~A biopsy from 1 to 2 cm2 will be performed in healthy peritoneum~- Adipose tissue samples : will be collected during surgery for breast reconstruction
Study: NCT00563888

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NET
Description: Narrative Exposure Therapy for traumatized survivors of organized violence
Study: NCT03083925

Intervention type: DEVICE
Intervention: TIPS
Description: Transjugular Intrahepatic Portosystemic Shunt

Intervention type: DEVICE
Intervention: TIPS
Description: Transjugular Intrahepatic Portosystemic Shunt
Study: NCT01034514

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-time Position Management system
Description: Standard of Care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Discovery ST multislice PET/CT scanner
Description: Standard of Care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infinia Hawkeye SPECT/CT gamma camera
Description: Standard of Care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pinnacle3 treatment planning system
Description: Standard of Care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SKYLight nuclear camera
Description: Standard of Care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTPA
Description: 1 mCi; inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TECHNETIUM TC 99M MAA
Description: 3 mCi; iv
Study: NCT03694275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: TAK-935 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: TAK-935 tablets
Study: NCT01274845

Intervention type: OTHER
Group type: OTHER
Intervention: Heliox mechanical ventilation
Description: Mechanical ventilation (MV) with air-oxygen at baseline, then 1 hour of heliox (helium-oxygen) MV and then return to MV with air-oxygen.
Study: NCT00743301

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Palm olein vs olive oil and lard
Description: 17E% from test fat is incorporated into three rolls and a piece of cake

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Palm olein vs olive oil and lard
Description: 17E% from test fat is incorporated into three rolls and a piece of cake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palm olein vs olive oil and lard
Description: 17E% from test fat is incorporated into three rolls and a piece of cake
Study: NCT03394001

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound infiltration
Description: Before skin closure,the subcutaneous tissue and skin all around the wound will be infiltrated by 20 mL of the drug then closure of the skin will be done.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound infiltration
Description: Before skin closure,the subcutaneous tissue and skin all around the wound will be infiltrated by 20 mL of the drug then closure of the skin will be done.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: 20 ml of 1% Lidocaine solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac tromethamine
Description: 20 mL of saline with 30 mg ketorolac
Study: NCT03362047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riciguat Group
Description: Patients will be administered 12 weeks Riciguat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan Group
Description: Patients will be administered 12 weeks Macitentan
Study: NCT03849313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: AVT02, a proposed similar biological product (biosimilar) of Humira which contains adalimumab . Adalimumab is a recombinant, fully human monoclonal immunoglobulin G1 (IgG1) antibody that binds specifically and with high affinity to the soluble and transmembrane forms of tumor necrosis factor (TNF)-α thereby inhibiting the binding of TNF-α with its receptor, and inhibiting TNF -α's biological function.~Tumor necrosis factor-α is a naturally occurring cytokine that is key to normal inflammatory and immune responses. Elevated levels of TNF-α are found in the synovial fluid of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis patients and psoriasis plaques and play an important role in both the pathologic inflammation and joint destruction that are hallmarks of these inflammatory diseases

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: AVT02, a proposed similar biological product (biosimilar) of Humira which contains adalimumab . Adalimumab is a recombinant, fully human monoclonal immunoglobulin G1 (IgG1) antibody that binds specifically and with high affinity to the soluble and transmembrane forms of tumor necrosis factor (TNF)-α thereby inhibiting the binding of TNF-α with its receptor, and inhibiting TNF -α's biological function.~Tumor necrosis factor-α is a naturally occurring cytokine that is key to normal inflammatory and immune responses. Elevated levels of TNF-α are found in the synovial fluid of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis patients and psoriasis plaques and play an important role in both the pathologic inflammation and joint destruction that are hallmarks of these inflammatory diseases
Study: NCT03856970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgestin®
Description: 30 μg/1500 μg tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: 600 μg tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide
Description: 5 mg tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: 0.25 mg tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-3718
Description: 500-mg film-coated tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-3718
Description: 500-mg film-coated tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-3718
Description: 500-mg film-coated tablets for oral administration
Study: NCT04132479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500mg
Description: 1000mg taken orally every 12 hours for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 500mg
Description: 1000mg taken orally every 12 hours for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinidazole 500mg
Description: 500mg taken orally every 12 hours for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20mg
Description: 20mg taken orally every 12 hours for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin 500mg
Description: 1000mg taken orally every 12 hours for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 500mg
Description: 1000mg taken orally every 12 hours for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tinidazole 500mg
Description: 500mg taken orally every 12 hours for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole 20mg
Description: 20mg taken orally every 12 hours for 14 days
Study: NCT04044430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02545946

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vessel loop
Description: using the vessel loop to hold the place of the surgical wound that is made during I\&D

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional I&D with or without packing
Description: abscess will be drained with a traditional I\&D with or without packing (as deemed appropriate by ER doctor)
Study: NCT02632877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone with MODD
Description: Patients with diabetic foot ulcer will be treated three times a day with a smooth layer (standar finger tip unit 0.5g for an area of 100 to 120 square centimeters) of KitosCell Q (Pirfenidone with MODD) in form of gel and the wound will be covered with a bandage.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketanserin
Description: Patients will be administered ketanserin twice a day usign the standar finger tip unit (0.5g for an area of 100 to 120 square centimeters) and the wound will be covered with a bandage. This arm is a control for evolution of diabetic foot ulcer.
Study: NCT02478307

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Meditation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Cognitive Therapy
Study: NCT00531206

Intervention type: DRUG
Intervention: Tipranavir

Intervention type: DRUG
Intervention: Ritonavir
Description: low dose
Study: NCT01906541

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ex-vivo gene-therapy
Description: transplantation autologous CD34+ cells, transduced with a SIN gammaretroviral vector
Study: NCT01785836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone Formulation A
Description: Dapsone Formulation A applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone Formulation B
Description: Dapsone Formulation B applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone Formulation C
Description: Dapsone Formulation C applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapsone 5% Gel
Description: Dapsone 5% gel (ACZONE®) applied twice daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
Study: NCT01631864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: LCZ696 was provided as 400 mg tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine
Description: amlodipine was provided as 5 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to LCZ696 and amlodipine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo to LCZ696 and amlodipine.
Study: NCT00046865

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupressure therapy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: acupressure therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: management of therapy complications

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: management of therapy complications

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nausea and vomiting therapy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: nausea and vomiting therapy

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: nausea and vomiting therapy
Study: NCT00483496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ti02 pigmentary 3% alone (formula RV3131A-MV1211)
Study: NCT02498431

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous coronary intervention
Description: a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous coronary intervention
Description: a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronary angiography
Description: is a procedure performed along with cardiac catheterization that uses X-ray imaging to see your heart's blood vessels

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronary angiography
Description: is a procedure performed along with cardiac catheterization that uses X-ray imaging to see your heart's blood vessels

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: coronary angiography
Description: is a procedure performed along with cardiac catheterization that uses X-ray imaging to see your heart's blood vessels

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stent, Medronic Resolute Integrity
Description: A stent is placed in an artery as part of a procedure called percutaneous coronary intervention (PCI) to restore blood flow through narrow or blocked arteries. A stent helps support the inner wall of the artery in the months or years after PCI.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent, Medronic Resolute Integrity
Description: A stent is placed in an artery as part of a procedure called percutaneous coronary intervention (PCI) to restore blood flow through narrow or blocked arteries. A stent helps support the inner wall of the artery in the months or years after PCI.
Study: NCT03639831

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Proprietary, standardized botanical extract
Description: 2 capsules/ day providing the proprietary botanical extract as unique active ingredient

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (maltodextrin)
Description: 2 capsules/ day providing no active component
Study: NCT04201054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: 50 mg of fluconazole administered orally in a single dose.
Study: NCT03695237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate (LA)
Description: Administered intramuscularly as an injection
Study: NCT01149109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide and lomustine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Study: NCT04725474

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: visugromab (CTL-002)
Description: monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: visugromab (CTL-002)
Description: monoclonal antibody
Study: NCT04324203

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Three-dimensional Virtual Reality and Horticultural Therapy
Description: VR is a realistic, three-dimensional, and virtual environment formed by a combination of computer software and hardware
Study: NCT02956785

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mg Dinoprostone; CTS, UK

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 mg Dinoprostone vaginal tablet; Pfizer, UK

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aquacryl hydrogel rod; HPSRx Enterprises, USA
Study: NCT04095481

Intervention type: DEVICE
Intervention: Obalon Navigation/Touch System
Description: The NTS Compatible Obalon Balloon System does NOT require the use of radiographic verification prior to the inflation of the intragastric balloon
Study: NCT00605215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Laquinimod will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to laquinimod will be administered per schedule specified in the arm description.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avonex®
Description: Avonex® will be administered per dose and schedule specified in the arm description.
Study: NCT01300728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NewGam 10% IVIG
Description: Subjects will be randomized to receive either an infusion of IVIG at 0.4 g/kg or every 14 days for two months for a total of five infusions.~Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio. Twenty-five subjects will receive IVIG and 25 subjects will receive placebo.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized to receive either an infusion of 0.9% saline solution (placebo) every 14 days for two months for a total of five infusions. Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio.
Study: NCT04528160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education and exercise
Description: PNE will be conducted in line with international guidelines and will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience. Exercise will included genera exercise delivered at moderate intensity.